focus -WSS

focus

author：hotspot 2025-09-28 01:30:54 - browse：387

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Inaction leaves children at risk from dangerous chemotherapy drug

knowledge

WSS

The inclusion problem at the heart of rehabilitation research

Intellia plays down concerns on accidental germline transmission

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Trans patients at the end of life deserve respect and dignity

Flu vaccine reformulation won't be easy, manufacturers warn

Listen: Vivek Ramaswamy's star turn & leaky drug data

entertainment

focus

hotspot

Walensky prepares to leave CDC — and Congress — behind

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

BioMarin wins approval for gene therapy to treat hemophilia A

There's an unseen cost to disruptive road

Dobbs anniversary: the lost opportunity of abortion as health care

FDA endorses new sterilization method for medical devices

Trump demands the U.S. pay no more for drugs than other countries … again

Prior authorization reform is both possible and imperative

Peter Hotez and the public health issue of online harassment

How to make over

entertainment

Inaction leaves children at risk from dangerous chemotherapy drug

CVS is on a mission to consolidate health care. Will it work?

HPV vaccine, cervical cancer study delivers historic results

Immunocompromised patients offer clues on chronic Covid

To bolster infectious disease surveillance, genomics powerhouses team up

California store owner shot dead in dispute over displaying Pride flag: Police

entertainment

hotspot

knowledge

focus